Cytomegalovirus immune globulin - Biotest

Drug Profile

Cytomegalovirus immune globulin - Biotest

Alternative Names: BT-084; BT-094; CMV-Gyn; Cytotect; Cytotect 70; Cytotect CP; Cytotect FH; HCMV-specific hyperimmune globulin - Biotest; Human cytomegalovirus immunoglobulin; Human normal immunoglobulin; Megalotect; Neocytotect

Latest Information Update: 03 Sep 2015

Price : $50

At a glance

  • Originator Biotest
  • Developer Biotest AG
  • Class Antivirals; Immunoglobulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cytomegalovirus infections
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Cytomegalovirus infections

Most Recent Events

  • 03 Sep 2015 Biotest completes enrolment in its phase III trial for Cytomegalovirus infections (Prevention) in Austria, Belgium, Germany, Hungary and Italy (EudraCT2007-004692-19)
  • 01 Jan 2013 Merz Pharma acquires marketing rights for Neocytotect® in Russia, from Biotest AG
  • 29 May 2009 Phase-III clinical trials in Cytomegalovirus infections (prevention) in Italy (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top